Get Royalty Pharma PLC (RPRX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
RPRX Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced +11.02% Royalty Pharma plc price and volume Combination chart with 2 data series. Chart represents Royalty Pharma plc price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has 2 Y ...
RPRX Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced +8.42% Royalty Pharma plc price and volume Combination chart with 2 data series. Chart represents Royalty Pharma plc price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has 2 Y ...
Royalty Pharma(RPRX.US)将于05月08日盘前发布财报 富途资讯05/03 09:00 新闻稿:PureTech宣布年度业绩 -37- 该集团继续持有许可证协议下的权利,并有合同义务向Royalty Pharma支付其收到的部分版税。因此,该集团 道琼斯04/30 14:00 FDA批准ADSTILADRIN的第二个药物产品生产设施;Ferring从Royalty Pharma获得最终...
Stock information RPRX Stock information Latest quarterly earnings Q1 2025 Results call Press Release Presentation Pre-quarterly results communication 10-Q Quarterly Report Q1 2025 Transcript View all Why invest in Royalty Pharma Latest news & results Events calendar...
Royalty Pharma所有资讯 新闻 公告 评级 这位Royalty Pharma内部人士的11%股份被出售了 根据我们所见,内部人士在过去12个月里在Royalty Pharma plc(纳斯达克:RPRX)中为净卖家。也就是说,内部人士出售的股票数量超过了他们购买的数量。 Simply Wall St20:07 Royalty Pharma | 10-Q:2025财年一季报 美股SEC公告05/08...
Get real-time Royalty Pharma (RPRX N) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing.
Royalty Pharma reports strong Q4 and FY 2024 financial growth, with projected 2025 Portfolio Receipts between $2.9 and $3.05 billion.
Stocks Royalty Pharma Reports 17% Growth in Portfolio Receipts to $839 Million and Raises 2025 Financial Guidance May 8, 2025 • Quiver Quantitative Stocks Fund Update: C WorldWide Group Holding A/S opened a $13.9M position in $RPRX stock May 5, 2025 • Quiver Quantitative ...
Technical stocks chart with latest price quote for Royalty Pharma Plc Cl A, with technical analysis, latest news, and opinions.